Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12:501-13.
Dec 1, 2007Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Dec 1, 2007Cancer Cell 2007; 12:501-13
Fröhling Stefan, Jiang Jingrui, Schittenhelm Marcus, Lee Benjamin H, Griffin James D, Stone Richard M, Heinrich Michael C, Deininger Michael W, Druker Brian J, Golub Todd R, Teckie Sewit, Ebert Benjamin L, Scholl Claudia, Levine Ross L, Loriaux Marc, Boggon Titus J, Bernard Olivier A, Berger Roland, Döhner Hartmut, Döhner Konstanze, Gilliland D Gary
[Weight loss and night sweats with unexpected tumor localization]
Oberholzer C, Sawatzki M, Rothermundt C. [Weight loss and night sweats with unexpected tumor localization]. Praxis 2007; 96:1911-4.
Nov 28, 2007[Weight loss and night sweats with unexpected tumor localization]
Nov 28, 2007Praxis 2007; 96:1911-4
Oberholzer C, Sawatzki M, Rothermundt Christian
Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients
Coburn N, Govindarajan A, Law C, Gueller U, Kiss A, Ringash J, Swallow C, Baxter N. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol 2007; 15:500-7.
Nov 17, 2007Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients
Nov 17, 2007Ann Surg Oncol 2007; 15:500-7
Coburn Natalie G, Govindarajan Anand, Law Calvin H L, Gueller Ulrich, Kiss Alex, Ringash Jolie, Swallow Carol J, Baxter Nancy N
Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions
Burster T, Kalbacher H, Verhelst S, Weber E, Falk K, Rotzschke O, Dunn S, Boehm B, Marin-Esteban V, Driessen C. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions. Biochemical pharmacology 2007; 74:1514-23.
Nov 15, 2007Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions
Nov 15, 2007Biochemical pharmacology 2007; 74:1514-23
Burster Timo, Kalbacher Hubert, Verhelst Steven H L, Weber Ekkehard, Falk Kirsten, Rotzschke Olaf, Dunn Shannon, Boehm Bernhard O, Marin-Esteban Viviana, Driessen Christoph
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Jörger M, Hollema H, Féty R, Van der Vijgh W, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Boddy A, Calvert H, Jodrell D, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, Sleeboom H, Izquierdo M, Schellens J. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8.
Nov 1, 2007Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Nov 1, 2007Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8
Jörger Markus, Hollema Harry, Féty Régine, Van der Vijgh Wjf J F, Hempel Georg, Chatelut Etienne, Karlsson Mats, Wilkins Justin, Tranchand Brigitte, Schrijvers Ad H G J, Twelves Christian, Beijnen Jos H, Boddy Alan V, Calvert Hilary, Jodrell Duncan I, Huitema Alwin D R, Richel Dick J, Dittrich Christian, Pavlidis Nikolas, Briasoulis Evangelos, Vermorken Jan B, Strocchi Elena, Martoni Andrea, Sorio Roberto, Sleeboom Henk P, Izquierdo Miguel A, Schellens Jan H M
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
Jörger M, Huitema A, Huizing M, Willemse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British journal of clinical pharmacology 2007; 64:622-33.
Nov 1, 2007Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
Nov 1, 2007British journal of clinical pharmacology 2007; 64:622-33
Jörger Markus, Huitema A D R, Huizing M T, Willemse P H B, de Graeff A, Rosing H, Schellens J H M, Beijnen J H, Vermorken J B
Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome
Knauer M, Haid A, Ammann K, Lang A, Offner F, Türtscher M, Cerkl P, Wenzl E. Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome. World J Surg Oncol 2007; 5:114.
Oct 11, 2007Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome
Oct 11, 2007World J Surg Oncol 2007; 5:114
Knauer Michael, Haid Anton, Ammann Karlheinz, Lang Alois, Offner Felix, Türtscher Martina, Cerkl Peter, Wenzl Etienne
Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial
Coburn N, Gueller U, Baxter N, Kiss A, Ringash J, Swallow C, Law C. Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial. Int J Radiat Oncol Biol Phys 2007; 70:1073-80.
Oct 1, 2007Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial
Oct 1, 2007Int J Radiat Oncol Biol Phys 2007; 70:1073-80
Coburn Natalie G, Gueller Ulrich, Baxter Nancy N, Kiss Alex, Ringash Jolie, Swallow Carol J, Law Calvin H L
Standardization of pathologic complete response rates in breast cancer treatment
Knauer M, Devries A, Wenzl E, Haid A. Standardization of pathologic complete response rates in breast cancer treatment. Breast Cancer Res Treat 2007; 110:395-6.
Sep 13, 2007Standardization of pathologic complete response rates in breast cancer treatment
Sep 13, 2007Breast Cancer Res Treat 2007; 110:395-6
Knauer Michael, Devries Alexander, Wenzl Etienne, Haid Anton
Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Ruhstaller T, Thürlimann B, Köberle D, von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. JCO 2007; 25:4025-6; author reply 4026-7.
Sep 1, 2007Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Sep 1, 2007JCO 2007; 25:4025-6; author reply 4026-7
Ruhstaller Thomas, Thürlimann Beat, Köberle Dieter, von Moos Roger
Reducing the risk of early recurrence in hormone-responsive breast cancer
Thürlimann B. Reducing the risk of early recurrence in hormone-responsive breast cancer. Ann Oncol 2007; 18 Suppl 8:viii8-17.
Sep 1, 2007Reducing the risk of early recurrence in hormone-responsive breast cancer
Sep 1, 2007Ann Oncol 2007; 18 Suppl 8:viii8-17
Thürlimann Beat
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
Hartmann J, Grünwald V, Kanz L, Käfer G, Pintoffl J, Meisinger I, Huober J, Horger M, Schleicher J, Mayer F, German sarcoma group. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110:861-6.
Aug 15, 2007Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
Aug 15, 2007Cancer 2007; 110:861-6
Hartmann Joerg T, Grünwald Viktor, Kanz Lothar, Käfer Gabriele, Pintoffl Jan, Meisinger Ines, Huober Jens, Horger Marius, Schleicher Jan, Mayer Frank, German sarcoma group
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.
Aug 6, 2007Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Aug 6, 2007J Clin Oncol 2007; 25:3846-52
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Thürlimann Beat, Öhlschlegel Christian, Braye Stephen, Orosz Zsolt, Neven Patrick, Raffoul Johnny, Rasmussen Birgitte Bruun, Dell'Orto Patrizia, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells
Enzler T, Gillessen Sommer S, Dougan M, Allison J, Neuberg D, Oble D, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood 2007; 110:954-61.
Aug 1, 2007Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells
Aug 1, 2007Blood 2007; 110:954-61
Enzler Thomas, Gillessen Sommer Silke, Dougan Michael, Allison James P, Neuberg Donna, Oble Darryl A, Mihm Martin, Dranoff Glenn
Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC
Lanz C, Früh M, Thormann W, Cerny T, Lauterburg B. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. Journal of separation science 2007; 30:1811-20.
Aug 1, 2007Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC
Aug 1, 2007Journal of separation science 2007; 30:1811-20
Lanz Christian, Früh Martin, Thormann Wolfgang, Cerny Thomas, Lauterburg Bernhard H
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
Klaeser B, Wiederkehr O, Köberle D, Mueller A, Bubeck B, Thürlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007; 18:1329-34.
Aug 1, 2007Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
Aug 1, 2007Ann Oncol 2007; 18:1329-34
Klaeser B, Wiederkehr O, Köberle Dieter, Mueller A, Bubeck B, Thürlimann Beat
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
Roth A, de Braud F, Seymour M, Widmer L, Glynne-Jones R, Leslie M, Wernli M, Maibach R, Rufibach K, Borner M, Köberle D, Saletti P, Bernhard J, Falk S, Stupp R, Fazio N, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23.
Aug 1, 2007Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
Aug 1, 2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23
Roth Arnaud D, de Braud Filippo, Seymour Matthew, Widmer Lukas, Glynne-Jones Robert, Leslie Martin, Wernli Martin, Maibach Rudolf, Rufibach Kaspar, Borner Markus M, Köberle Dieter, Saletti Piercarlo, Bernhard Jürg, Falk Stephen, Stupp Roger, Fazio Nicola, Swiss Group for Clinical Cancer Research
Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial
Adamina M, Heberer M, Zuber M, Oertli D, Frey D, Gueller U, Zajac P, Schumacher R, Rosenthal R, Weber W, Spagnoli G. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp Clin Trials 2007; 29:165-81.
Jul 17, 2007Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial
Jul 17, 2007Contemp Clin Trials 2007; 29:165-81
Adamina Michel, Heberer Michael, Zuber Markus, Oertli Daniel, Frey Daniel M, Gueller Ulrich, Zajac Paul, Schumacher Reto, Rosenthal Rachel, Weber Walter P, Spagnoli Giulio C
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
Seeholzer N, Thürlimann B, Köberle D, Hess D, Korte W. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23.
Jul 1, 2007Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
Jul 1, 2007Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23
Seeholzer Niels, Thürlimann Beat, Köberle Dieter, Hess Dagmar, Korte Wolfgang
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H, 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-44.
Jul 1, 2007Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Jul 1, 2007Ann Oncol 2007; 18:1133-44
Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, 10th St. Gallen conference